A Study to Analyze an Ultra-low-dose Chest CT Technique to Screen for Pulmonary Arteriovenous Malformations in Pediatric Patients with Hereditary Hemorrhagic Teleangiectasia


About this study

This study aims to develop a novel ultra-low dose chest CT technology for use in HHT patients and to determine the lowest possible radiation dose that is achievable without sacrificing the diagnostic quality.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Ages 1 to 17 years.
  • Diagnosed with positive HHT causing. mutations or based on Curacao criteria.

Exclusion Criteria: 

  • Acute respiratory distress.
  • Unstable cardiovascular status.
  • Pneumothorax, hemoptysis.
  • Pulmonary edema.
  • Pulmonary emboli.
  • Fractured ribs or other chest trauma.
  • Recent bronchoscopy.
  • Lung transplantation.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Nadir Demirel, M.D., M.S.

Open for enrollment

Contact information:

Supriya Behl B.S.

(507) 538-1440


More information


Publications are currently not available

Mayo Clinic Footer